Supernus Pharmaceuticals, Inc.
SUPN Nasdaq
SEC CIK 1356576
Follow Supernus Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$226.8M
+18% vs same quarter last year
Net income
$20.9M
+146.4% vs same quarter last year
EPS, diluted
$0.35
+143.8% vs same quarter last year
Operating cash flow
$6.6M
+110.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $719M | −$38.6M |
| FY24 | $661.8M | $73.9M |
| FY23 | $607.5M | $1.3M |
| FY22 | $667.2M | $60.7M |
| FY21 | $579.8M | $53.4M |
| FY20 | $520.4M | $127M |
| FY19 | $392.8M | $113.1M |
| FY18 | $408.9M | $111M |
| FY17 | $302.2M | $57.3M |
| FY16 | $215M | $91.2M |
| FY15 | $147.5M | $13.9M |
| FY14 | $92.7M | −$10.9M |
| FY13 | $12M | −$92.3M |
| FY12 | $1.5M | −$46.3M |
| FY11 | $803K | $53.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 89.6% | −8.7% | −5.4% |
| FY24 | 88.2% | 12.3% | 11.2% |
| FY23 | 86.2% | −0.9% | 0.2% |
| FY22 | 86.9% | 6.9% | 9.1% |
| FY21 | - | 14.8% | 9.2% |
| FY20 | 89.9% | 33.4% | 24.4% |
| FY19 | 95.8% | 37.8% | 28.8% |
| FY18 | 96.2% | 35.3% | 27.1% |
| FY17 | 95% | 32.9% | 19% |
| FY16 | 94.4% | 25.2% | 42.4% |
| FY15 | 94.3% | 14.1% | 9.5% |
| FY14 | 93.8% | −5.7% | −11.8% |
| FY13 | 90.8% | −515.2% | −767.7% |
| FY12 | - | −2849.3% | −3127.3% |
| FY11 | - | −4701.4% | 6701.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $46M |
| FY24 | $171.2M |
| FY23 | $110.5M |
| FY22 | $116.4M |
| FY21 | - |
| FY20 | $135M |
| FY19 | $140.4M |
| FY18 | $128.1M |
| FY17 | $112.6M |
| FY16 | $65.2M |
| FY15 | $32.4M |
| FY14 | −$25.1M |
| FY13 | −$59.6M |
| FY12 | −$48M |
| FY11 | −$36.9M |
- Supernus Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Supernus Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −5.4% | −30.6% |
| FY24 | 11.2% | −47% |
| FY23 | 0.2% | −58% |
| FY22 | 9.1% | −80.4% |
| FY21 | 9.2% | −71.8% |
| FY20 | 24.4% | −62.2% |
| FY19 | 28.8% | −46.2% |
| FY18 | 27.1% | −49.6% |
| FY17 | 19% | −45.9% |
| FY16 | 42.4% | −36% |
| FY15 | 9.5% | −37.8% |
| FY14 | −11.8% | −35.5% |
| FY13 | −767.7% | −37.1% |
| FY12 | −3127.3% | −29.1% |
| FY11 | 6701.7% | −27.9% |